Novocure Ltd Cash Flow Conversion Efficiency
Novocure Ltd cash flow conversion efficiency. Based on the latest financial reports, Novocure Ltd (NVCR) has a cash flow conversion efficiency ratio of -0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.52 Million) by net assets ($330.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Novocure Ltd (2013–2025)
Cash flow conversion efficiency of Novocure Ltd from 2013 to 2025. This chart illustrates how Novocure Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NVCR live share price for real-time trading data and today's change.
Novocure Ltd Cash Flow Conversion Ratio Explained
Novocure Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Novocure Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novocure Ltd ranked by their cash flow conversion efficiency. Also see NVCR stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cardinal Energy Ltd
TO:CJ
|
0.119x |
|
Metrovacesa SA
MC:MVC
|
0.099x |
|
IGNITIS GRUPE SP.GDR/1
F:IGV
|
0.048x |
|
H Lundbeck A/S
CO:HLUN-A
|
0.014x |
|
Yantai Dongcheng Pharmaceutical Co Ltd
SHE:002675
|
0.044x |
|
Beijing Caishikou Department Store Co Ltd
SHG:605599
|
0.091x |
|
Galapagos N.V.
AS:GLPG
|
-0.024x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
Annual Cash Flow Conversion Efficiency for Novocure Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Novocure Ltd from 2013 to 2025. Review Novocure Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $340.47 Million | $-49.03 Million | -0.144x | -96.71% |
| 2024-12-31 | $360.18 Million | $-26.37 Million | -0.073x | +63.81% |
| 2023-12-31 | $362.50 Million | $-73.34 Million | -0.202x | -389.89% |
| 2022-12-31 | $441.17 Million | $30.79 Million | 0.070x | -65.38% |
| 2021-12-31 | $410.49 Million | $82.76 Million | 0.202x | -3.11% |
| 2020-12-31 | $476.53 Million | $99.15 Million | 0.208x | +70.23% |
| 2019-12-31 | $217.79 Million | $26.62 Million | 0.122x | +835.72% |
| 2018-12-31 | $112.26 Million | $-1.86 Million | -0.017x | +94.31% |
| 2017-12-31 | $113.56 Million | $-33.13 Million | -0.292x | +61.40% |
| 2016-12-31 | $142.34 Million | $-107.59 Million | -0.756x | -89.80% |
| 2015-12-31 | $250.82 Million | $-99.88 Million | -0.398x | +47.50% |
| 2014-12-31 | $97.88 Million | $-74.24 Million | -0.759x | -147.18% |
| 2013-12-31 | $171.78 Million | $-52.72 Million | -0.307x | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more